0QAV.L

Nanobiotix S.A. [0QAV.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0QAV.L Stock Summary

Top 10 Correlated ETFs

0QAV.L

Top 10 Correlated Stocks

0QAV.L

In the News

0QAV.L Financial details

Company Rating
-
Market Cap
255.67M
Income
-101.72M
Revenue
9.4M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
04 Sep 2024
P/E
-4.13
Forward P/E
-
PEG
-0.36
P/S
50.13
P/B
-4.51
P/C
-
P/FCF
-9.08
Quick Ratio
0.46
Current Ratio
0.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.14%
Revenue last 5Y
6.54%
Revenue Q/Q
-4.47%
EPS Q/Q
-9.09%
-
-
-
-
SMA20
29.05%
SMA50
25.22%
SMA100
41.14%
Inst Own
-
Inst Trans
-
ROA
-145%
ROE
145%
ROC
4.89%
Gross Margin
100%
Oper. Margin
-685%
Profit Margin
-872%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.624-10.38
52W High
-54.7%
52W Low
+353%
RSI
76.09
Rel Volume
1.81
Avg Volume
8.59K
Volume
15.52K
Perf Week
14.97%
Perf Month
49.01%
Perf Quarter
30.17%
Perf Half Y
35.22%
-
-
-
-
Beta
1.252
-
-
Volatility
0.21%, 0.46%
Prev Close
-2.16%
Price
4.53
Change
-0.22%

Something similar

Top by Market Cap
V
AVGO
GOOG
AMZN
0YXG.L
Top Correlated ETFs
LKOR.DE
IQQK.DE
FLXK.DE
DBX8.DE
3110.HK
Top Correlated Stocks
NANO.PA
JKCEMENT.NS
RHFL.NS
6886.HK
ABAN.NS
Similar Market Cap
CZFS
KAVVERITEL.NS
HTAB
INCO
NCZ

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 8.59K
  • Market Capitalization 255.67M
  • Employee 101
  • CEO Mr. Laurent Levy Ph.D.
  • Headquarters Paris,FR
  • IPO Date 2014-02-13
  • Website https://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.